$3.97
0.010.25%
Last update: Nov 11, 10:11 AM
GT Biopharma Inc
GTBPNASDAQ
GT Biopharma rose 486.0% from $0.68 to $3.96, ahead of the S&P 500's +9.8%. Its worst day was Oct 21 (−26.0%), and its low came Sep 3 at $0.25.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-20.75 missed the $-7.75 estimate on $0.00 revenue.
+26.6% · S&P 500 0.0%
EPS of $-121.00 was reported on $0.00 revenue.
−2.3% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $-2.75 missed the $-2.00 estimate on $0.00 revenue.
−10.3% · S&P 500 −1.2%
EPS of $-3.00 missed the $-2.00 estimate on $0.00 revenue.
−0.5% · S&P 500 −0.2%
GT Biopharma closed at its lowest level of the year, 62.7% below where the year started.
−10.8% · S&P 500 +1.0%
GT Biopharma closed at its highest level of the year, 1620.9% above where the year started.
+35.1% · S&P 500 −0.4%
Where it ended: a close of $3.96 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-2.50).
Nothing in the past 12 months.
All GTBP analyst actionsNothing in the past 12 months.
All GTBP dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GTBP and SPY from Benzinga historical bars. Not investment advice.
